Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gitt, A. K.
Right arrow Articles by Betriu, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gitt, A. K.
Right arrow Articles by Betriu, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Antiplatelet therapy in acute coronary syndromes

Anselm K. Gitt1,* and Amadeo Betriu2

1 Institut fuer Herzinfarktforschung Ludwigshafen an der Universitaet Heidelberg, Bremser Str. 79, 67063 Ludwigshafen, Germany
2 Universitat de Barcelona, Villarroel, 170, Barcelona 8036, Spain

* Corresponding author. Tel: +49 621 503 4000; fax: +49 621 503 4044. E-mail address: gitta{at}klilu.de

Antiplatelet agents are an essential component of the treatment of acute coronary syndromes (ACS). In numerous clinical trials, aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors have been shown to reduce the incidence of ischaemic events in patients with unstable angina, non-ST-elevation myocardial infarction, and ST-elevation myocardial infarction. Aspirin is appropriate for lifelong therapy in patients with ACS. Clopidogrel is recommended for most patients with ACS for short- or long-term therapy, depending on the patient’s level of risk. New antiplatelet agents with distinct pharmacological properties may offer advantages, including faster onset of action, greater potency, and reversibility of effects. The treatment of ACS has evolved considerably in the past decade, with a trend towards greater consistency of care and more widespread provision of evidence-based therapies. Registries and surveys offer opportunities to educate health care providers on compliance with current guideline recommendations for the management of patients with ACS, which should lead to improved clinical outcomes.

Key Words: Aspirin • Clopidogrel • Myocardial infarction • Percutaneous coronary intervention • Stroke • Drug-eluting stent


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.